| Field | Specification |
|---|---|
| Mfr No | |
| Clonality | |
| Host | |
| Immunogen | A synthesized peptide derived from human CFD was used as the immunogen for the CFD antibody. |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Overview
CFD Antibody / Complement Factor D is a anti-CFD Rabbit antibody Recombinant Rabbit Monoclonal clone 30C23 supplied in Liquid format. Recommended for workflows such as Western blot (WB) with listed reactivity in Human.
Key elements and design rationale
- Target: CFD
- Antibody details: Rabbit, Recombinant Rabbit Monoclonal, clone 30C23, isotype Rabbit IgG
- Format: Liquid
- Applications (as listed): WB
Biological background
Complement factor D is secreted primarily by adipocytes and monocytes. Unlike many complement proteins, it circulates in an active form but with a restricted substrate range, cleaving only factor B bound to C3b. Studies with CFD antibody have shown that this specificity is essential for tight regulation of the alternative pathway. Because the alternative pathway provides continuous low level activity, factor D ensures rapid amplification once pathogens are detected, making it indispensable for innate defense.
Deficiency of Complement factor D is rare but results in increased susceptibility to infections, particularly with Neisseria species. Research with CFD antibody has confirmed that lack of factor D disrupts C3 convertase formation, impairing complement activation. Conversely, excessive factor D activity has been linked to inflammatory and autoimmune conditions, such as age related macular degeneration. Clinical studies have explored factor D inhibition as a therapeutic strategy to dampen overactive complement in retinal and renal disease.
CFD antibody is widely used in immunohistochemistry, western blotting, and ELISA. Immunohistochemistry demonstrates expression in adipose tissue and macrophages, while western blotting identifies circulating and tissue associated protein. ELISA with CFD antibody measures factor D levels in serum, supporting biomarker studies in complement driven diseases. These applications highlight the clinical and research significance of detecting Complement factor D.
By supplying validated CFD antibody reagents,
Research relevance and current trends
- Connecting protein-level changes to phenotype using orthogonal readouts (genetic perturbation, transcriptomics, imaging).
- Considering isoforms and post-translational regulation when interpreting protein-level changes.
- Comparing results across species and model systems with matched controls.
Common research applications
- Western blotting: compare relative abundance and activation-state changes across conditions.
Interpret changes in signal alongside appropriate controls and, when relevant, in parallel with total-protein or pathway readouts.
Notes for experimental interpretation
- Signal can reflect expression level, isoform composition, and post-translational state; interpret results in the context of your model system and stimuli.
- Species differences and sample matrices can influence epitope recognition; prioritize matched controls and orthogonal confirmation when feasible.
Antibody notes: Monoclonal antibodies provide a defined epitope recognition profile that can support consistent comparisons across experiments.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
